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Abstract: Background and Objectives: In anticoagulated atrial fibrillation (AF) patients, the validity
of models recommended for the stratification of the risk ratio between benefits and hemorrhage
risk is limited. Cerebral small vessel disease (SVD) represents the pathologic substrate for primary
intracerebral hemorrhage and ischemic stroke. We hypothesize that biological markers—both
circulating and imaging-based—and their possible interaction, might improve the prediction of
bleeding risk in AF patients under treatment with any type of oral anticoagulant. Materials and
Methods: The Strat-AF study is an observational, prospective, single-center hospital-based study
enrolling patients with AF, aged 65 years or older, and with no contraindications to magnetic resonance
imaging (MRI), referring to Center of Thrombosis outpatient clinic of our University Hospital for
the management of oral anticoagulation therapy. Recruited patients are evaluated by means of a
comprehensive protocol, with clinical, cerebral MRI, and circulating biomarkers assessment at baseline
and after 18 months. The main outcome is SVD progression—particularly microbleeds—as a selective
surrogate marker of hemorrhagic complication. Stroke occurrence (ischemic or hemorrhagic) and
the progression of functional, cognitive, and motor status will be evaluated as secondary outcomes.
Circulating biomarkers may further improve predictive potentials. Results: Starting from September
2017, 194 patients (mean age 78.1 ± 6.7, range 65–97; 61% males) were enrolled. The type of AF was
paroxysmal in 93 patients (48%), and persistent or permanent in the remaining patients. Concerning
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the type of oral anticoagulant, 57 patients (29%) were on vitamin K antagonists, and 137 (71%) were
on direct oral anticoagulants. Follow-up clinical evaluation and brain MRI are ongoing. Conclusions:
The Strat-AF study may be an essential step towards the exploration of the role of a combined clinical
biomarker or multiple biomarker models in predicting stroke risk in AF, and might sustain the
incorporation of such new markers in the existing stroke prediction schemes by the demonstration
of a greater incremental value in predicting stroke risk and improvement in clinical outcomes in a
cost-effective fashion.
Keywords: atrial fibrillation; anticoagulation; stroke; intracerebral hemorrhage; cerebral small vessel
disease; brain MRI; circulating biomarkers
1. Introduction
Thromboprophylaxis with oral anticoagulation effectively reduces stroke risk in patients with atrial
fibrillation (AF). Benefits must be balanced against the risk of bleeding, with intracranial hemorrhage
being the most feared. Stroke and bleeding risk stratification schemes are aimed at identifying patients
who may benefit most from different types of oral anticoagulation (vitamin K antagonists vs. direct
oral anticoagulants). Currently, such schemes (e.g., CHADS2VASC2 and HASBLED scores) rely only
on clinical information, the validity of which remains controversial and needs to be improved. In
AF patients, advanced imaging technology such as magnetic resonance imaging (MRI), has led to
the increased detection of asymptomatic brain changes, mainly those related to small vessel disease
(SVD), which is the pathologic substrate for primary intracerebral hemorrhage (ICH) [1–6]. These
changes have also been proven to strongly predict stroke risk [2,5]. Such imaging findings, obtained
both at baseline and in terms of lesion progression over time, could be used as additional markers
for risk stratification [3,7]. Furthermore, markers of coagulation activation, including prothrombin
fragment 1+2, thrombin–antithrombin complex, D-dimer, time in therapeutic range for warfarin, and
drug dosage for new anticoagulants, may be also studied as cofactors. Preliminary data suggest
that circulating biomarkers of endothelial dysfunction, hypercoagulable state, and inflammation may
further enhance risk prediction [4].
The validity of the currently recommended models for the stratification of risk ratio between
benefits and hemorrhagic risk in anticoagulated AF patients is limited. These models do not specifically
take intracranial hemorrhage into account, which is indeed the most severe hemorrhagic complication [8].
Our hypothesis is that biological markers—both circulating and imaging-based, and their possible
interaction—might improve the prediction of bleeding risk in AF patients treated with any type of
oral anticoagulant. Neuroimaging biomarkers of SVD—particularly microbleeds—may serve as a
selective surrogate marker of hemorrhagic complications. Circulating biomarkers assessed together
with imaging may further improve predictive potentials.
In this scenario, we set up the prospective observational Strat-AF study, primarily aimed at
investigating circulating biomarkers and MRI markers (baseline and progression) of SVD as surrogate
markers for the prediction of cerebral bleeding in a cohort of patients with AF on oral anticoagulants.
Secondary outcomes included stroke occurrence (either ischemic or hemorrhagic) and the progression
of functional, cognitive, and motor status.
2. Materials and Methods
Stratification of Cerebral Bleeding Risk in AF, Strat-AF, Strat-AF is an observational, prospective,
single-center hospital-based study enrolling patients with AF, referring to the Center of Thrombosis
outpatient clinic of our University Hospital for the management of oral anticoagulation therapy.
Medicina 2019, 55, 626 3 of 11
2.1. Inclusion Criteria
• Diagnosis of AF and ongoing oral anticoagulation therapy;
• Aged ≥ 65 years;
• No contraindications to MRI.
2.2. Exclusion Criteria
• Inability or refusal to undergo cerebral MRI;
• Inability to give an informed consent.
All subjects gave their informed consent for inclusion before they participated in the study. The study
was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the
Ethics Committee of the Careggi University Hospital (Project identification code 16RFAP, approved on
March 2017).
Sample size was estimated based on a feasibility criterion (i.e., the real flow of patients to the
Thrombosis outpatient clinic of Careggi Hospital). Yearly, approximately 600 patients with AF on
oral anticoagulation refer to the outpatient clinic. Considering a foreseeable rate of ineligible patients
and refusals, we originally estimated to contact approximately 300 patients in one year fulfilling
the inclusion criteria. Starting from September 2017, consecutive eligible patients were invited to
participate in the study. The initial foreseen period for enrollment was 12 months, but in order to
augment the number of included patients, we extended the enrollment period to 18 months.
2.3. Clinical Assessment
All enrolled patients were assessed at baseline by means of a standard clinical/functional protocol
collecting information on vascular risk factors (particularly hypertension and diabetes), dietary habits,
previous cerebrovascular events, general neurological and functional status, cognitive performances,
mood and gait disorders, and general neurological examination.
In detail, clinical data were collected about social and medical history; a standard cardiovascular
and neurological examination, including office blood pressure measurement, were performed.
Functional status was assessed using the Activities of Daily Living scale and the Instrumental
Activities of Daily Living scale [9,10]; mood assessment using the Geriatric Depression Scale [11];
motor performance using the Short Physical Performance Battery [12]; daytime sleepiness using the
Epworth Sleepiness Scale [13]; and quality of life using the EuroQol Visual Analog Scale [14]. Dietary
habits were assessed by means of the questionnaire on the adherence to the Mediterranean diet [15].
A comprehensive multi-domain cognitive assessment, including global functioning, orientation,
memory, attention, executive functions, language, speed, and motor control was administered to each
included patient.
The cognitive domains assessed by means of the extensive battery of tests were as follows:
• Global cognitive efficiency, by means of the Montreal Cognitive Assessment (MoCA): it is a
10-minute cognitive screening tool created to detect mild cognitive impairment (MCI), suggested
from the harmonization standards of the National Institute of Neurological Disorders and
Stroke—Canadian Stroke Network (NINDS-CSN) and thought to be specifically sensitive to
frontal, attention, and executive deficits [16–18]. It covers eight cognitive domains: short-term
and delayed verbal memory; visuospatial abilities; executive functions; attention; concentration;
working memory; language; and orientation (score range 0–30)
• Verbal memory, by means of the Rey Auditory-Verbal Learning Test (RAVLT) and the Short Story
Recall Test [19,20]. The RAVLT and Short Story Recall Test measure several components of verbal
memory, such as immediate free recall, verbal learning, and retention of information after a certain
period of time. Two scores are obtained from the RAVLT: immediate free recall (range 0–75) and
delayed free recall (range 0–15). The Short Story Recall Test has a total score obtained by the
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mean number of elements correctly remembered on the immediate and delayed recalls (score
range 0–28).
• Attention, by means of the Visual Search test [21]. This is a number cancellation task that requires
visual selectivity at fast speed, and assesses the capacity for sustained attention and accuracy of
visual scanning (score range 0–60). The Colour Word Stroop test was also used [22]. It is a measure
of concentration effectiveness and deals with response inhibition and selective attention. The
activity required by this test is a selective processing of only one visual feature while continuously
blocking out the processing of others. The execution time and the errors committed are recorded.
• Language, by means of:
i. Semantic verbal fluency test: a test allowing the semantic evaluation of lexical access [23].
Three categories were tested: car brands, fruits, and animals. The total score was given by
the sum of the number of words produced for each category in one minute.
ii. Sentence construction test: a test used to evaluate the verbal ability to construct a meaningful
sentence starting from a set of two or three words (score range 0–25) [19].
All raw test scores were demographically corrected according to Italian population normative
data, and adjusted scores were then recoded as normal, borderline, or abnormal according to equivalent
scores (ES) methodology [24]. ES methodology is a non-parametric norming method based on
percentiles and is independent from the distribution form. ES is an ordinal 5-point scale (ranging from
0 to 4), and the main point of ES methodology is to fix the outer tolerance limit of the left queue of the
adjusted scores so that it is possible to assess, with a known risk of error (<5%), the cut-off splitting
the bottom 5% of the population and representing pathological performance (ES = 0). At the other
end of the scale, ES = 4 indicates an optimal performance (equal to or better than the median). ES = 1
indicates a borderline performance (an adjusted score between the outer and inner confidence limits
for the fifth centile of the normal population), while the remaining ES scores of 2 and 3 represent
normal performances.
The diagnosis of MCI requires at least one altered score (ES = 0) plus one borderline score (ES = 1)
in any cognitive test included in the neuropsychological battery.
2.4. Cerebral Magnetic Resonance Imaging Assessment
Cerebral MRI scans were performed at baseline, and again 18 months after enrollment. The brain
imaging protocol was planned and set up by imaging personnel with different expertise and skills, as
suggested by current guidelines [25].
Baseline and follow-up MRI examinations are performed on an Ingenia 1.5-Tesla MRI unit
(Philips Healthcare, Eindhoven, The Netherlands). Our standardized MRI protocol consisted of
the following sequences: sagittal T1-weighted spin-echo (repetition time (TR) = 547 ms; echo time
(TE) = 12 ms; slice thickness = 5 mm; interslice spacing = 0.5 mm; matrix size = 320 × 250; field
of view (FOV) = 23 cm × 23 cm; number of signals averaged (NSA) = 1), coronal T2-weighted
fast spin-echo (TR = 3347 ms; TE = 110 ms; slice thickness = 5 mm; interslice spacing = 0.5 mm;
matrix size = 512 × 322; FOV = 22 cm × 22 cm; NSA = 2); axial fluid-attenuated inversion recovery
(FLAIR) (TR = 11,000 ms; TE = 125 ms; inversion time (TI) = 2800 ms; slice thickness = 5 mm; interslice
spacing = 0.5 mm; matrix size = 384× 204; FOV = 23 cm× 23 cm; NSA = 2); axial gradient-echo T2* (GRE)
(TR = 534 ms; TE = 23 ms; flip angle (FA) = 18; slice thickness = 5 mm; interslice spacing = 0.5 mm;
matrix size = 256 × 185; FOV = 23 cm × 23 cm; NSA = 1); axial diffusion-weighted imaging (DWI) (TR
= 3891 ms; TE = 75 ms; slice thickness = 5 mm; interslice spacing = 0.5 mm; matrix size = 164 × 162;
FOV = 23 cm × 23 cm; NSA = 2); gradient-echo 3D T1-weighted (TR = 7.5 ms; TE = 3.4 ms; TI = 950,
slice thickness = 1 mm; matrix size = 256 × 241; FOV = 25.6 cm × 25.6 cm; NSA = 1) followed by
multiplanar reconstruction (MPR) in axial, coronal, and sagittal planes. DWI images were obtained by
single-shot echo-planar spin-echo sequences according to the Stejskal–Tanner method. The diffusion
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gradients were applied in three orthogonal directions (x, y, z) with two b-values (0 and 1000 s/mm2)
to form the isotropic DWI images at b 1000 s/mm2. Apparent diffusion coefficient (ADC) maps were
generated automatically by the software provided by the manufacturer from isotropic DWI images and
concurrent images with a b value of 0 s/mm2 by using the following equation: ADC = -ln [S(b)/S(0)]/b,
where b indicates the b value and S(b) and S(0) are the signal intensities of images with b values equal
to 1000 and 0, respectively.
Each MRI scan was evaluated by an expert neuroradiologist, and a written medical report was
provided to patients. Neurologists involved in the project revised the report before returning it to
patients, so that any incidental findings could be handled according to individual needs.
Qualitative and quantitative analyses of SVD-related features on MRI are under way.
The following features related to SVD will be assessed: i) lacunar infarcts, either silent or not;
ii). white matter hyperintensities; iii) microbleeds; iv) dilated perivascular spaces; v) cortical and
subcortical atrophy; vi) superficial siderosis [5].
Non-lacunar infarcts will be visually assessed in terms of number and location of lesions.
2.5. Circulating Biomarker Assessment
Venous blood samples were collected after enrollment and placed at -80 ◦C for long-term storage.
Besides routine parameters (complete blood count (CBC), prothrombin time (PT), activated
partial thromboplastin time (APTT), D-dimer, fibrinogen, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides, glucose, creatinine, glomerular filtration rate (GFR), alanine
aminotransferase, C-reactive protein (CRP), N Terminal pro B-type natriuretic peptide, Lp(a), troponin),
several circulating biomarkers will be evaluated:
• Endothelial function biomarkers;
• Pro- and anti-inflammatory molecules;
• Metalloproteinases and their inhibitors;
• Markers of renal function;
• Markers of blood clotting activation and of fibrinolytic system of coagulation activation,
including prothrombin fragment 1+2, thrombin–antithrombin complex, D-dimer, and endogenous
thrombin potentials;
• Genetic polymorphisms that may influence the effect of anticoagulants and plasmatic
microRNA profile.
The list of biomarkers under investigation is detailed in Table 1. The biological material (serum,
plasma, DNA) is properly conserved to allow the evaluation of further biomarkers by specific or global
assessment strategies (e.g., metabolomics profiling, targeted or whole-exome sequencing).
Proteomic and genetic biomarkers will be evaluated with high-multiplex immunoassays or
high-throughput technologies such as Bio-Plex Multiplex Immunoassay System (BioRad), Proximity
Extension Assay (Olink) technology, H-nuclear magnetic resonance spectroscopy (Bruker BioSpin),
real-time PCR (Life Technologies), droplet digital PCR (BioRad), and high-throughput sequencing
(Illumina).
Biosamples were processed using standard and harmonized operating procedures.
Clinical data are registered electronically in the web-based registry (http://www.strat-af.it/). Quality
controls are done on a weekly basis. Imaging data are instantly checked for protocol conformity.
The same clinical/functional assessment and brain MRI will be repeated 18 months after enrollment.
An interim telephone follow-up interview will be scheduled approximately three months before the
final clinical assessment.
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Table 1. Circulating biomarkers under investigation in the Strat-AF study.
Category Biomarkers Name
Markers of endothelial function
- von Willebrand Factor (vWF)
- Tissue Factor Pathway Inhibitor (TFPI)
Pro- and anti-inflammatory molecules
- Chemokine (C-C motif) ligand 3 (CCL3)
- Interleukin (IL)-1β (IL-1β),
- IL-1 Receptor antagonist (IL-1RA)
- IL-2
- IL-6
- IL-8
- IL-10
- IL-12 P40
- Tumor Necrosis Factor Alpha (TNF-Alfa)
- Intercellular Adhesion Molecule-1 (ICAM-1)
- Vascular cell adhesion molecule-1 (VCAM-1)
- Vascular Endothelial Factor (VEGF)
Metalloproteinases
- Matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, MMP-12
- Tissue Inhibitor of Metalloproteinases (TIMP)-1, TIMP-2, TIMP-3, TIMP-4
Markers of coagulation activation
- Endogenous thrombin potential (ETP)
- Plasminogen activator inhibitor-1 (PAI-1) antigen
- Prothrombin fragment 1+2 (F1+2)
- Thrombin antithrombin complexes (TAT)
- Tissue factor
- Plasminogen Activator Inhibitor-1 (PAI-1) antigen
- Clot lysis time (CLT)
Genetic polymorphisms and plasmatic
miRNA
- CES1 rs2244613
- CES1 rs8192935
- ABCB1 rs148738
- VKORC1 G3673A or –1639G>A rs9923231
- CYP2C9*2 rs1799853
- CYP2C9*3 rs1057910
- CYP2C9*5 rs28371686
- CYP2C9*6 rs9332131
- CYP4F2 V433M rs2108622 C>T
- GGCX rs11676382
- Plasmatic miRNA profiling by real-time PCR
2.6. Primary Endpoint
The primary study endpoint will be SVD progression, evaluated by means of the control
MRI performed 18 months after enrollment. The progression of lacunar infarcts and microbleeds
will be evaluated as the appearance of at least one new lesion, respectively. White matter
hyperintensities progression will be rated by means of the visual Rotterdam Progression Scale
(score range from 0 to 9) [26]. Absence or presence of progression (0 or 1, respectively) will be rated in
three periventricular regions (frontal caps, occipital caps, bands), four subcortical white matter regions
(frontal, parietal, occipital, temporal), basal ganglia, and the infratentorial region. Post-processing and
ratings will be centralized and performed by expert and reliable observers, blinded to clinical data.
2.7. Secondary Endpoints
Secondary endpoints will be:
1. Stroke occurrence (ischemic or hemorrhagic).
2. Considering data from medical history and available laboratory and imaging exams, new major
cerebrovascular events will be recorded as ischemic or hemorrhagic strokes. Ischemic strokes will
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be further categorized in subtypes according to the TOAST classification system [27]. Hemorrhagic
strokes will be classified according to lesion type and location.
3. Progression of global functioning, cognitive, and motor performances.
4. Progression in cognitive status will be determined by the occurrence of a diagnosis of MCI or
dementia, and defined according to performances on the comprehensive neuropsychological
test battery (evaluated as normal or abnormal by means of national normative data), and
functional status.
5. The change in global functional status will be based on the Activities of Daily Living and
Instrumental Activities of Daily Living scales, and the worsened condition will be defined as
the loss of at least one item (i.e., the patient became dependent for an item function that was
preserved at baseline evaluation).
6. Motor status will be evaluated by means of the Short Physical Performance Battery. Based on the
total score (range 0–12), at each visit individuals will be categorized as having normal (SPPB ≥ 11)
or impaired mobility (SPPB ≤ 10), and variations in performance categories over time (baseline
vs. 18 months) will be evaluated for each patient.
2.8. Statistical Analyses
Multivariate regression analyses will be performed in order to identify independent predictors
of SVD and its progression. Among the variables of interest, apart from the clinical ones and those
assessed by means of conventional MRI, special attention will be paid to the relationship with advanced
neuroimaging features and circulating biological markers.
Cerebral SVD and its progression—particularly microbleeds, which are considered the main
expression of a bleeding-prone state—will be studied as outcome variables in multivariate regression
models, considering the independent effect of all relevant markers, including major vascular risk
factors and anticoagulant treatment with different types of anticoagulants (vitamin K antagonists vs.
direct thrombin antagonists or factor Xa antagonists), and circulating biomarkers.
Interactions of circulating biomarkers with imaging markers, and types of oral anticoagulants
will also be analyzed. Bonferroni correction will be applied in multivariate models to counteract the
problem of multiple comparisons.
The multivariable prediction of the risk of SVD progression in this cohort of AF patients on oral
anticoagulants will be studied as the methodological background for clinical research in the setting
of stroke prevention in patients with AF (i.e., for designing and sample sizing studies potentially
adopting the above indicated biomarkers as surrogate markers of the clinical outcomes).
3. Results
Starting from September 2017 until March 2019, 617 patients referring to the outpatient clinic
of the Center of Thrombosis for oral anticoagulants therapy control were screened for inclusion in
the study. As shown in Figure 1, 423 patients (68%) were excluded because of MRI contraindications
(n = 227) or refusal (n = 196). The remaining 194 patients were enrolled. Demographic and clinical
characteristics of the baseline sample are shown in Table 2: mean age was 78.1 ± 6.7 (range 65–97)
years, 118 (61%) were males, and mean education was 9.1 ± 4.3 (range 2–19) years. The type of AF was
paroxysmal in 93 patients (48%), and persistent or permanent in the remaining patients. Concerning
the type of oral anticoagulant, 57 patients (29%) were on vitamin K antagonists, and 137 (71%) were on
direct oral anticoagulants. Follow-up clinical evaluation and brain MR are ongoing.
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Table 2. Baseline sample demographic and clinical characteristics.
Mi –Max Baseline Sample n = 194
Age, years (mean ± SD) 65–97 78.1 ± 6.7
Years of education 2–19 9.1 ± 4.3
Sex (% males) - 61% (n = 118)
Hypertension - 82% (n = 159)
Hypercholesterolemia - 48% (n = 94)
Diabetes - 13% (n = 25)
Smoking habits - 61% (n = 119)
History of stroke - 22% (n = 42)
Alcohol consumption - 51% (n = 100)
Paroxysmal AF - 48% (n = 93)
Type of oral anticoagulant
Vitamin K antagonists - 29% (n = 57)
Direct oral anticoagulants - 71% (n = 137)
4. Discussion
The Strat-AF study is an ongoing, single-center, longitudinal observation study evaluating elderly
patients with AF on oral anticoagulation for primary or secondary prevention of stroke. The project
foresees, in consecutive elderly patients with AF attending the Center for Thrombosis outpatient clinic
of Careggi University Hospital for management of oral anticoagulation therapy, the implementation of
a comprehensive neurological, neuropsychological, and functional evaluation together with blood
sample collection for the determination of circulating biological markers (in relation to the hemorrhagic
risk profile) and brain MRI for the determination of brain parenchyma lesions as surrogate markers
of a bleeding-prone state. The Strat-AF cohort will allow the evaluation of the possible role of
biological markers, including clinical, circulating, and neuroimaging-based, and their interaction, on
the prediction of bleeding risk in AF patients under treatment with any type of oral anticoagulant.
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Neuroimaging biomarkers of SVD, particularly microbleeds, will be tested as a selective surrogate
marker of such complication. Circulating biomarkers assessed together with imaging might further
improve the predictive potentials. Active enrollment started from September 2017 and ended in March
2019. The baseline study cohort included 194 elderly patients. Follow-up assessments are now ongoing.
One first major comment arises from the fact that in order to reach the number of enrolled patients,
more than 600 patients had to be screened. Of these, more than half were excluded. Main reasons for
exclusion were refusal (46%) and MRI contraindications (54%). Thus, the method under evaluation
(i.e., brain MRI) will not be feasible for all AF patients, but just for those without contraindication.
According to our experience, about one-quarter of patients would not be included in such a new
stratification risk schema.
Overall, the study protocol seems feasible, and nearly all included patients completed
the evaluation.
Our results will provide a unique opportunity to achieve preliminary data about SVD progression
as a surrogate marker of the effect of antithrombotic treatments used for stroke prevention in patients
with AF. The longitudinal design of the study may also provide clues about the possible association of
SVD and its progression with clinical endpoints. Thrombo-embolic and bleeding risk will be assessed
using the clinical risk scores CHADS2VASC2 and HAS-BLED respectively. Such predictive models
will be completed studying the effect of neuroimaging features, particularly those related to SVD, and
circulating biological markers, in order to provide preliminary knowledge about the incremental value
of such markers.
Conclusive evidence about the predictive value of these markers in single patients can only come
from adequately powered large prospective follow-up studies, and few efforts are already under way.
Prospective multicenter studies such as the CROMIS 2 (clinical relevance of microbleeds in stroke;
ClinicalTrials.gov Identifier NCT02513316), ICH because of oral anticoagulants: prediction of the risk
by MRI (HERO, Hirulog Early Reperfusion/Occlusion Trial; ClinicalTrials.gov Identifier NCT02238470),
and CMB-NOW (CMBs during NOACs or warfarin therapy in non-valvular AF patients with acute
ischemic stroke; ClinicalTrials.gov Identifier NCT02356432) are ongoing. Main results from CROMIS-2
have been recently published: among the 1490 patients with AF enrolled after their ischemic stroke,
the presence of CMBs significantly increased the risk of symptomatic ICH (adjusted hazard ratio 3.67,
95% CI 1.27–10.60), confirming that CMBs are independently associated with symptomatic ICH risk,
and could be used to inform anti-coagulation decisions. In this study, after 24 months of follow-up,
14 patients had an intracerebral hemorrhage. The very low number of events did not allow the
establishment of whether a CMBs threshold exists. Moreover, the study does not foresee a control MRI,
so no information is available concerning the possible role of CMBs progression. A recent meta-analysis
assessed the association between CMBs and future ICH risk in ischemic stroke patients with AF taking
oral anticoagulants. The authors concluded that the presence of CMBs on MRI and the dichotomized
cutoff of ≥5 CMBs might identify subgroups of patients with high ICH risk [28], but these data need to
be confirmed before they can be used in clinical practice.
5. Conclusions
Long-term oral anticoagulation is the mainstay therapy for ischemic stroke prevention in patients
with AF. Available stroke and bleeding risk stratification schemes are aimed at identifying patients
who may benefit most from oral anticoagulation [29]. Such schemes (e.g., CHADS2VASC2, HAS-BLED
scores) currently rely only on clinical information, the validity of which remains controversial and
needs to be improved. Attempts have been made to refine the risk stratification scores by the addition
of various biomarkers (blood, urine, cardiac, and cerebral imaging), but data are still inconclusive as to
whether the costs are justified [30].
The Strat-AF study may be an essential step towards the exploration of the role of a combined
clinical biomarker or multiple biomarker models in predicting stroke risk in AF, and might sustain the
incorporation of such new markers in the existing stroke prediction schemes by the demonstration
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of a greater incremental value in predicting stroke risk and improvement in clinical outcomes in a
cost-effective fashion.
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